No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention
…, RV Wainstein, L Ohno-Machado, JM Kirshenbaum… - American heart …, 2003 - Elsevier
Background No-reflow occurring during percutaneous coronary intervention (PCI) has been
associated with poor inhospital outcomes. The objectives of this analysis were to evaluate …
associated with poor inhospital outcomes. The objectives of this analysis were to evaluate …
[PDF][PDF] A new Tc-99m-labeled myocardial imaging agent, hexakis (t-butylisonitrile)-technetium (I)[Tc-99m TBI]: initial experience in the human
…, A Davison, MJ Abrams, JM Kirshenbaum… - Journal of nuclear …, 1984 - Soc Nuclear Med
METHODS Preparationof Tc-99m hexakis (t-butylisonitrile) technetium (I). The agent Tc-99m
TBI was prepared by ligand exchange from a sterile pyrogen-free solution of the zinc …
TBI was prepared by ligand exchange from a sterile pyrogen-free solution of the zinc …
Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation.
SJ Bhatia, JM Kirshenbaum, RJ Shemin, LH Cohn… - Circulation, 1987 - Am Heart Assoc
Most patients with severe congestive heart failure have secondary pulmonary hypertension (PHT).
Elevation of pulmonary vascular resistance (PVR) to greater than 480 dynes.sec.cm-5 …
Elevation of pulmonary vascular resistance (PVR) to greater than 480 dynes.sec.cm-5 …
[HTML][HTML] Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction …
…, RF Sequeira, F Leya, JM Kirshenbaum… - Journal of the American …, 1994 - Elsevier
Objectives. The aim of our study was to determine a superior tbrombolytic regimen from
three: anistreplase (APSAC), frontloaded recombinant tissue-type plasminogen activator (rt-PA) …
three: anistreplase (APSAC), frontloaded recombinant tissue-type plasminogen activator (rt-PA) …
Responses of coronary arteries of cardiac transplant patients to acetylcholine.
…, GH Mudge, JM Kirshenbaum… - The Journal of …, 1988 - Am Soc Clin Investig
Accelerated coronary atherosclerosis is a major cause of graft failure after heart transplantation.
Graft atherosclerosis is typically diffuse and difficult to detect even with coronary …
Graft atherosclerosis is typically diffuse and difficult to detect even with coronary …
Effect of large oral doses of ascorbic acid on uric acid excretion by normal subjects
…, MW Johnson, JM Kirshenbaum… - Clinical …, 1981 - Wiley Online Library
The effects of large oral doses of ascorbic acid on renal clearance and excretion of uric acid
were studied in nongouty subjects because ascorbic acid has been reported to increase …
were studied in nongouty subjects because ascorbic acid has been reported to increase …
Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
JM Kirshenbaum, RA Kloner, EM Antman… - Circulation, 1985 - Am Heart Assoc
Esmolol is a new ultra short-acting (half-life [t1/2] beta 9 min) beta 1-adrenergic-receptor
antagonist reported to have no intrinsic sympathomimetic activity. The safety and efficacy of …
antagonist reported to have no intrinsic sympathomimetic activity. The safety and efficacy of …
[HTML][HTML] Intentional hydroxychloroquine overdose treated with high-dose diazepam: an increasing concern in the COVID-19 pandemic
Introduction Recent attention on the possible use of hydroxychloroquine and chloroquine to
treat COVID-19 disease has potentially triggered a number of overdoses from …
treat COVID-19 disease has potentially triggered a number of overdoses from …
Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy
JM Kirshenbaum, RF Kloner, N McGowan… - Journal of the American …, 1988 - Elsevier
The hemodynamic responses io esmolol, an ultrashort-acting (t 1/3 = 9 min) beta 1 -adrenergic
receptor antagonist, were examined in 16 patients with myocardial ischemia and …
receptor antagonist, were examined in 16 patients with myocardial ischemia and …
Ethanol intoxication complicating intravenous nitroglycerin therapy
TL SHOOK, JM KIRSHENBAUM… - Annals of internal …, 1984 - acpjournals.org
Excerpt Intravenous Nitroglycerin, occasionally in large doses, is increasingly being used
for patients with unstable angina, variant angina, and left ventricular failure, and to control …
for patients with unstable angina, variant angina, and left ventricular failure, and to control …